Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin
Дата публикации: 19-06-2026 07:06:00

New indication concerns combination with pembrolizumab, as neoadjuvant and adjuvant treatment in patients with resectable MIBC who are ineligible for cisplatin

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
2EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan0526-06-2026
3EMA Recommends Extension of Therapeutic Indications for Encorafenib0503-07-2026
4FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer5508-07-2026
5New targeted therapy shows promising early results in advanced pancreatic cancer2705-07-2026
6FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC5724-06-2026
7New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026
8Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma5730-06-2026
9Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
10Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer7801-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.esmo.org.